TORONTO, April 18 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biotechnology company dedicated to the development and commercialization of cancer therapies, today announced that its Common Shares have been approved for listing on the Toronto Stock Exchange (TSX) and will no longer trade on the TSX Venture Exchange. Trading on the TSX is expected to commence today, April 18th, 2006, at the market opening under the symbol “BMR”.
“We believe the transition to the TSX from the TSX Venture reflects the maturity of Bradmer’s lead product candidate Neuradiab. This transition is in keeping with our strategy to advance the corporate progress of the Company by broadening the base of potential investors to support our clinical development,” said Mark C. Rogers, M.D., Chief Executive Officer of Bradmer.
About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)
Bradmer Pharmaceuticals is a biotechnology company focused on the development and commercialization of new and innovative cancer therapies. Bradmer’s lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer. To date, over US$60 million has been spent on research and development of the licensed treatment, which has been used in over 160 patients with excellent results and has completed Phase II clinical trials conducted by researchers at Duke University. Bradmer is currently in the process of organizing a multi-center clinical trial of the licensed treatment. Neuradiab was recently granted Orphan Drug Status by the U.S. Food and Drug Administration.
Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.
Except for historical information, this press release may contain forward- looking statements, which reflect the Company’s current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.
Bradmer Pharmaceuticals Inc.
CONTACT: Bradmer Pharmaceuticals Inc.: Mr. Brian Brohman, Chief FinancialOfficer, Phone: (502) 657-6038, Fax: (502) 657-6039, E-mail:bbrohman@bradmerpharma.com, Internet: www.bradmerpharma.com; InvestorRelations: Ross Marshall, The Equicom Group Inc., Phone: (416) 815-0700(Ext. 238) , Fax: (416) 815-0080, E-mail: rmarshall@equicomgroup.com